What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry

The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey. Scheduled for April 13th, this year's edition follows the well-established Cannabis Capital Conference (CCC) and will take place at the luxurious Fontainebleau Miami Beach Hotel in Florida. The conference boasts an impressive lineup of keynote speakers and specialized leaders in psychedelics advisory, who will be discussing the latest trends and innovations in the field.

Below is a breakdown of some of the things you can expect at the amazing event.

Psychedelics 101

The conference will kick off with "Psychedelics 101," a panel that delves into the history of psychedelics and their importance in treating health conditions that conventional treatments have failed to address. The discussion will explore the ancestral use of psychedelics and the therapy surrounding their treatment, including preparation and integration. Panelists include Simeon Schnapper of JLS, Natalie Ginsberg from MAPS, Najla Guthrie, CEO of Wellbeing Digital Sciences, and Cody Shandraw of Ambria Capital. The panel will be moderated by Bryan Passman, Co-Founder of Hunter + Esquire.

Dr. Joe Tucker, CEO of Enveric

The first Fireside chat will feature Dr. Joe Tucker, CEO of Enveric Bio ENVB, in conversation with moderator Kaia Roman from Psycheceutical BWVI.

The Business of Consciousness

The second panel, "The Business of Consciousness," will examine the growth market of psychedelics, with insights from David Traylor, Sr. Managing Director of Golden Eagle Partners, Andrew Chomer from Integrated.VC, Dan Ahrens of AdvisorShares - which issues the AdvisorShares Psychedelics ETF PSIL, and Maria Velkova from Tabula Rasa. Todd Boren will moderate the

Tracking MDMA Approvals

The third panel will focus on tracking MDMA approvals, providing updates on MAPS' Phase 3 MDMA trials for PTSD, advanced Phase 2 trials by COMPASS Pathways CMPS (psilocybin for treatment-resistant depression), and MindMed MMDCF (LSD for general anxiety disorder). Panelists will also discuss changes in federal regulations, national surveys on psychedelic use, and the FDA's current regulations for advancing new mental health treatments. The panel will be moderated by Courtney Barnes and will feature Robert Velarde of Iter Investments, Michael Mullette from MAPS, Nick Kadysh, CEO of PharmAla Biotech, and George McBride, Chief Communications Officer at Clerkenwell Health.

Afternoon Keynote: Matthew Johnson from Johns Hopkins

Matthew Johnson of Johns Hopkins will deliver the afternoon keynote, providing valuable insights into the future of psychedelics research and development.

From the Ground Up: Infrastructure Built for Healing

The second Fireside chat will focus on building infrastructure for healing, with panelists Cody Shandraw of Ambria Capital and Tyler Zakovich. The conversation will be moderated by Daniel Carcillo, CEO of Wesana WSNAF.

Ketamine, Strength in Numbers

The fourth panel will discuss the off-label use of ketamine for various mental health conditions, different therapeutic approaches, the importance of integration, and the potential for misuse. Panelists include Kathryn Walker from Revitalist, Jeff Becker, CEO of Bexson, Cory Jones from Healing Maps, and Julia Mirer, Director of Strategy & Impact at Nushama. Matt Zorn of Yetter Coleman will moderate the discussion.

Lessons From Legal Psilocybin Markets

The fifth panel will explore lessons from legal psilocybin markets in Oregon, Colorado and Quebec. The discussion will cover the organization of license granting for production, delivery, and therapeutic support, as well as the ways legislation is guiding the practical application of psilocybin-assisted therapy. Panelists will also address the differences between legal and illegal practices and the current state of decriminalization, particularly in Colorado. Speakers include Rodman Law's Nadav Aschner, Joseph from Chacruna, Zappy Zapolin of Psycheceutical, and Justin Kirkland, Chief Science Officer at Optimi Health OPTHF. The panel will be moderated by Farrell Miller of Benzinga.

NextGen Psychedelics

The final panel, "NextGen Psychedelics," will discuss the current state of development of this subset of psychedelics, including the most important clinical trials and innovative substances. Panelists will also delve into the legal pathways for these substances, especially if they are not hallucinogenic, and their targeted indications. Featured speakers are Dr. Joseph Tucker from Enveric, Evan Levine, CEO of PsyBio Therapeutics, Claire Stawnyczy, CEO of Lophos, and James Gillian, Interim CEO of Tryp Therapeutics TRYPF. The panel will be moderated by Anne Donohoe from KCSA.

The 2023 Benzinga Psychedelics Capital Conference promises to be an enlightening and engaging event for all attendees, whether they are newcomers to the field or seasoned professionals. Don't miss this opportunity to connect with industry leaders, stay up to date on the latest trends, and gain valuable insights into the rapidly evolving world of psychedelics.